Monica Margoni

Monica Margoni

Auto-generated profile, based on publicly available information

Monica Margoni

Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2018 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
DBDamiano Baroncini
Damiano Baroncini
MZMauro Zaffaroni
Mauro Zaffaroni
LMLucia Moiola
Lucia Moiola
LLLorena Lorefice
Lorena Lorefice
GFGiuseppe Fenu
Giuseppe Fenu
AGAngelo Ghezzi
Angelo Ghezzi
Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p < 0.001), and it remained low during the whole follow-up (0.3 ± 0.2, p < 0.001). At last observation, 40% had disability worsening, but EDSS score remained <4 in 89%. One patient died at age of 23 years due to MS. One case of natalizumab-related progressive multifocal encephalopathy (PML) was recorded. Starting therapy before 12 years of age resulted in a better course of disease in multivariate analysis. Pediatric-MS patients benefited from interferons/copaxone, but the majority had to switch to more powerful drugs. Starting therapy before 12 years of age could lead to a more favorable outcome.

1 March 2024 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PPPaolo Preziosa
Paolo Preziosa
EPElisabetta Pagani
Elisabetta Pagani
AMAlessandro Meani
Alessandro Meani
LSLoredana Storelli
Loredana Storelli
MMMonica Margoni
Monica Margoni
Massimo FilippiMassimo Filippi
Massimo Filippi
Chronic inflammation may contribute to cognitive dysfunction and fatigue in patients with multiple sclerosis (MS). Paramagnetic rim lesions (PRLs) and choroid plexus (CP) enlargement have been proposed as markers of chronic inflammation in MS being associated with a more severe disease course. However, their relation with cognitive impairment and fatigue has not been fully explored yet. Here, we investigated the contribution of PRL number and volume and CP enlargement to cognitive impairment and fatigue in patients with MS. Brain 3T MRI, neurologic evaluation, and neuropsychological assessment, including the Brief Repeatable Battery of Neuropsychological Tests and Modified Fatigue Impact Scale, were obtained from 129 patients with MS and 73 age-matched and sex-matched healthy controls (HC). PRLs were identified on phase images of susceptibility-weighted imaging, whereas CP volume was quantified using a fully automatic method on brain three-dimensional T1-weighted and fluid-attenuated inversion recovery MRI sequences. Predictors of cognitive impairment and fatigue were identified using random forest. Thirty-six (27.9%) patients with MS were cognitively impaired, and 31/113 (27.4%) patients had fatigue. Fifty-nine (45.7%) patients with MS had ≥1 PRLs (median = 0, interquartile range = 0;2). Compared with HC, patients with MS showed significantly higher T2-hyperintense white matter lesion (WM) volume; lower normalized brain, thalamic, hippocampal, caudate, cortical, and WM volumes; and higher normalized CP volume (p from <0.001 to 0.040). The predictors of cognitive impairment (relative importance) (out-of-bag area under the curve [OOB-AUC] = 0.707) were normalized brain volume (100%), normalized caudate volume (89.1%), normalized CP volume (80.3%), normalized cortical volume (70.3%), number (67.3%) and volume (66.7%) of PRLs, and T2-hyperintense WM lesion volume (64.0%). Normalized CP volume was the only predictor of the presence of fatigue (OOB-AUC = 0.563). Chronic inflammation, with higher number and volume of PRLs and enlarged CP, may contribute to cognitive impairment in MS in addition to gray matter atrophy. The contribution of enlarged CP in explaining fatigue supports the relevance of immune-related processes in determining this manifestation independently of disease severity. PRLs and CP enlargement may contribute to the pathophysiology of cognitive impairment and fatigue in MS, and they may represent clinically relevant therapeutic targets to limit the impact of these clinical manifestations in MS.

27 September 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MMMonica Margoni
Monica Margoni
FRFrancesca Rinaldi
Francesca Rinaldi
ARAlice Riccardi
Alice Riccardi
SFSilvia Franciotta
Silvia Franciotta
PPPaola Perini
Paola Perini
PGPaolo Gallo
Paolo Gallo

1 June 2023 in Radiology
Verified
Journal Article
Closed access
MRMaria Assunta Rocca
Maria Assunta Rocca
MMMonica Margoni
Monica Margoni
MBMarco Battaglini
Marco Battaglini
AEArman Eshaghi
Arman Eshaghi
JIJeffrey Iliff
Jeffrey Iliff
Massimo FilippiMassimo Filippi
Massimo Filippi
MRI plays a central role in the diagnosis of multiple sclerosis (MS) and in the monitoring of disease course and treatment response. Advanced MRI techniques have shed light on MS biology and facilitated the search for neuroimaging markers that may be applicable in clinical practice. MRI has led to improvements in the accuracy of MS diagnosis and a deeper understanding of disease progression. This has also resulted in a plethora of potential MRI markers, the importance and validity of which remain to be proven. Here, five recent emerging perspectives arising from the use of MRI in MS, from pathophysiology to clinical application, will be discussed. These are the feasibility of noninvasive MRI-based approaches to measure glymphatic function and its impairment; T1-weighted to T2-weighted intensity ratio to quantify myelin content; classification of MS phenotypes based on their MRI features rather than on their clinical features; clinical relevance of gray matter atrophy versus white matter atrophy; and time-varying versus static resting-state functional connectivity in evaluating brain functional organization. These topics are critically discussed, which may guide future applications in the field.

1 July 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PPPaolo Preziosa
Paolo Preziosa
EPElisabetta Pagani
Elisabetta Pagani
MMMonica Margoni
Monica Margoni
MRMartina Rubin
Martina Rubin
LSLoredana Storelli
Loredana Storelli
Massimo FilippiMassimo Filippi
Massimo Filippi
The choroid plexus (CP) regulates immune functions and produces most CSF that circulates in the brain parenchyma through perivascular spaces, part of the glymphatic system. In multiple sclerosis (MS), CP enlargement and glymphatic dysfunction are associated with inflammatory activity, clinical disability, and brain damage, but their interrelation is unclear. We investigated whether glymphatic system dysfunction mediates the association between CP enlargement and brain damage in patients with MS. Brain fluid-attenuated inversion recovery, 3-dimensional T1-weighted, diffusion-weighted, and susceptibility-weighted sequences were obtained from 146 patients with MS and 72 healthy controls (HC). Glymphatic function was assessed using the diffusion along the perivascular space (DTI-ALPS) index, and CP volume was measured automatically. Patients with MS showed significantly higher white matter (WM) lesion and CP volumes (p < 0.001), and lower DTI-ALPS index, brain, WM, thalamic, and cortical volumes than HC (p ≤ 0.048). In patients with MS, higher CP volume correlated with a lower DTI-ALPS index (r = -0.305, false discovery rate p value = 0.001). Both measures were associated with higher total, periventricular, and juxtacortical (JC) WM lesion volumes (CP volume: r from 0.285 to 0.340, p-FDR ≤ 0.001; DTI-ALPS index: r from -0.301 to -0.444, p ≤ 0.001), and lower brain, thalamic, cortical, and WM volumes (CP volume: r from -0.246 to -0.405, p-FDR ≤ 0.006; DTI-ALPS index: from 0.269 to 0.497, p-FDR ≤ 0.003). The DTI-ALPS index partially mediated the associations of normalized choroid plexus volume with total, periventricular, and JC T2-hyperintense WM lesion volumes (standardized-β ranging from 0.073 to 0.115, relative effect ranging from 25.2% to 33.6%) and normalized brain, thalamic, cortical, and WM volumes (standardized-β ranging from -0.086 to -0.125, relative effect ranging from 25.3% to 52.7%). In MS, enlarged normalized CP volume may contribute to brain damage accumulation possibly through the promotion of a chronic proinflammatory state and the mediation of glymphatic system dysfunction.

4 July 2011 in Cephalalgia
Verified
Journal Article
Closed access
FMFerdinando Maggioni
Ferdinando Maggioni
MMMonica Margoni
Monica Margoni
GZGiorgio Zanchin
Giorgio Zanchin